Navigating TKI Selection in Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia

Nicholas Short, MD, discusses TKIs like ponatinib and combining them with other treatments for ALL.

Initial results from the phase 3 GIMEMA ALL2830 trial support the use of this chemotherapy-free approach as a new SOC for adult Ph-positive ALL.

Jose Tinajero, PharmD, BCOP, discusses the role of the pharmacist in treatment planning and management in chronic myeloid leukemia.

Jose Tinajero, PharmD, BCOP, discusses the role of the pharmacist in treatment planning and management in chronic myeloid leukemia.

Wendy Stock, MD, discusses how TKI-based, chemotherapy-free regimens are advancing Ph-positive ALL care toward durable, treatment-free remission.

Wendy Stock, MD, discussed the role of molecular testing in Ph-positive ALL and best practices for implementing this testing across clinical scenarios.

Michael J. Mauro, MD, discusses the evolution of TKIs for CML, factors for TKI selection, and ways that genetic mutations influence treatment efficacy.

Michael J. Mauro, MD, discusses how genetic alterations, such as BCR::ABL mutations, inform treatment decisions in CML.